SPTX (Seaport Therapeutics) EPS without NRI: $ (TTM As of Dec. 2025)


SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $21.43
! 1 Warning Sign
View Full Analysis

What is Seaport Therapeutics EPS without NRI?

Seaport Therapeutics SPTX +10.37% 11 EPS without NRI is $ as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,176 Biotechnology companies, Seaport Therapeutics ranks worse than 85033.93% on this metric.

Seaport Therapeutics's earnings per share without non-recurring items for the six months ended in Dec. 2025 was $-1.94.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Seaport Therapeutics's EPS without NRI or its related term are showing as below:

SPTX's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.8
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Seaport Therapeutics's EPS (Diluted) for the six months ended in Dec. 2025 was $-1.94.

Seaport Therapeutics's EPS (Basic) for the six months ended in Dec. 2025 was $-1.94.


Seaport Therapeutics  (NAS:SPTX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Seaport Therapeutics EPS without NRI Related Terms


Seaport Therapeutics EPS without NRI Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics EPS without NRI Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
EPS without NRI
-1.21 -1.94

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
EPS without NRI -1.21 -1.94

SPTX vs LXRX, DRTS, MGTX: EPS without NRI Comparison

For the Biotechnology subindustry, Seaport Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seaport Therapeutics PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seaport Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Seaport Therapeutics's PE Ratio without NRI falls into.


SPTX
11GF Score
Seaport Therapeutics Inc SPTX
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $ mean?
Seaport Therapeutics (SPTX) has a EPS without NRI of $ as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Seaport Therapeutics and its competitors. According to the industry distribution chart, Seaport Therapeutics ranks #999999 out of 1176 companies in the Biotechnology industry.
Is Seaport Therapeutics' EPS without NRI too high?
Seaport Therapeutics' current EPS without NRI is $. Based on the distribution chart, Seaport Therapeutics ranks #999999 out of 1176 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' EPS without NRI compare to LXRX and DRTS?
According to the Biotechnology industry distribution chart, Seaport Therapeutics ranks #999999 out of 1176 companies for EPS without NRI. This places Seaport Therapeutics in the lower half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,176 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Seaport Therapeutics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seaport Therapeutics's current EPS without NRI is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current EPS without NRI of $. The current EPS without NRI is $. Seaport Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current EPS without NRI is $ as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.43
Price